- Home
- HIO vs LRMR Comparison
HIO vs LRMR Comparison
Compare HIO & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIO | LRMR |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.0M | 316.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HIO | LRMR |
|---|---|---|
| Price | $3.70 | $3.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 305.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.52 | $1.61 |
| 52 Week High | $4.03 | $5.37 |
Technical Indicators
Market Signals| Indicator | HIO | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 41.46 |
| Support Level | $3.68 | $3.34 |
| Resistance Level | $3.75 | $4.01 |
| Average True Range (ATR) | 0.03 | 0.25 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 29.17 | 13.58 |
Price Performance
Historical ComparisonAbout HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.